- Home
- IOBT vs INMB Comparison
IOBT vs INMB Comparison
Compare IOBT & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- INMB
- Stock Information
- Founded
- IOBT 2014
- INMB 2015
- Country
- IOBT Denmark
- INMB United States
- Employees
- IOBT N/A
- INMB N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- IOBT Health Care
- INMB Health Care
- Exchange
- IOBT Nasdaq
- INMB Nasdaq
- Market Cap
- IOBT 57.2M
- INMB 49.2M
- IPO Year
- IOBT 2021
- INMB 2019
- Fundamental
- Price
- IOBT $0.73
- INMB $1.53
- Analyst Decision
- IOBT Buy
- INMB Hold
- Analyst Count
- IOBT 4
- INMB 3
- Target Price
- IOBT $3.50
- INMB $4.30
- AVG Volume (30 Days)
- IOBT 944.0K
- INMB 367.5K
- Earning Date
- IOBT 11-14-2025
- INMB 10-30-2025
- Dividend Yield
- IOBT N/A
- INMB N/A
- EPS Growth
- IOBT N/A
- INMB N/A
- EPS
- IOBT N/A
- INMB N/A
- Revenue
- IOBT N/A
- INMB $50,000.00
- Revenue This Year
- IOBT N/A
- INMB $191.43
- Revenue Next Year
- IOBT N/A
- INMB $12,299.51
- P/E Ratio
- IOBT N/A
- INMB N/A
- Revenue Growth
- IOBT N/A
- INMB 19.05
- 52 Week Low
- IOBT $0.32
- INMB $1.38
- 52 Week High
- IOBT $2.79
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- IOBT 43.86
- INMB 40.65
- Support Level
- IOBT $0.70
- INMB $1.45
- Resistance Level
- IOBT $0.83
- INMB $1.62
- Average True Range (ATR)
- IOBT 0.11
- INMB 0.10
- MACD
- IOBT -0.00
- INMB 0.01
- Stochastic Oscillator
- IOBT 30.72
- INMB 39.79
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.